Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 12, 2014, Pages 3441-3443

  Knoll, Bettina M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Antifungal therapy; Mucormycosis; Salvage therapy; Zygomycosis

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BILIRUBIN; ISAVUCONAZOLE; POSACONAZOLE; ANTIFUNGAL AGENT; NITRILE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; BRONCHOPNEUMONIA; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FAT INTAKE; FUNGUS GROWTH; GASTRIC BYPASS SURGERY; HISTOPATHOLOGY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY TUBULE ACIDOSIS; LETTER; LOADING DRUG DOSE; LUNG LAVAGE; LUNG MYCOSIS; LUNG RESECTION; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RHIZOPUS; SIDE EFFECT; SPUTUM CULTURE; STOMACH ACID; DRUG EFFECTS; ISOLATION AND PURIFICATION; LUNG DISEASES, FUNGAL; MICROBIAL SENSITIVITY TEST; ORAL DRUG ADMINISTRATION; STOMACH BYPASS;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; GASTRIC BYPASS; HUMANS; LUNG DISEASES, FUNGAL; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUCORMYCOSIS; NITRILES; PYRIDINES; RHIZOPUS; TRIAZOLES;

EID: 84929821439     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku311     Document Type: Letter

References (9)

1. Guinea J, Peláez T, Recio S et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52: 1396-400.
2. Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 2012; 8: 759-65.
3. Lee SM, Pryor AD. Future directions in bariatric surgery. Surg Clin North Am 2011; 91: 1373-95.
4. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010; 11: 41-50.
5. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588-90.
6. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
7. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-69.
8. Peixoto D, Gagne LS, Hammond SP et al. Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol 2014; 52: 1016-9.
9. Ervens J, Ghannoum M, Graf B et al. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection 2014; 42: 429-32.